Characteristics and clinical influence factors of arsenic species in plasma and their role of arsenic species as predictors for clinical efficacy in acute promyelocytic leukemia (APL) patients treated with arsenic trioxide

References

• Mcculloch D, Brown C. Retinoic acid and arsenic trioxide in the treatment of acute promyelocytic leukemia: current perspectives. Oncol Targets Ther. 2017;10:1585–1601.
   PubMed Web of Science ®Google Scholar
• Chen GQ, Shi XG, Tang W, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood. 1997;89(9):3345–3353.
   PubMed Web of Science ®Google Scholar
• Ghaffari SH, Momeny M, Bashash D, et al. Cytotoxic effect of arsenic trioxide on acute promyelocytic leukemia cells through suppression of NFkβ-dependent induction of hTERT due to down-regulation of Pin1 transcription. Hematology. 2012;17(4):198–206.
   PubMed Web of Science ®Google Scholar
• Ghaffari SH, Bashash D, Zaki Dizaji M, et al. Alteration in miRNA gene expression pattern in acute promyelocytic leukemia cell induced by arsenic trioxide: a possible mechanism to explain arsenic multi-target action. Tumor Biol. 2012;33(1):157–172.
   PubMedGoogle Scholar
• Breccia M, Lo-Coco F. Arsenic trioxide for management of acute promyelocytic leukemia: current evidence on its role in front-line therapy and recurrent disease. Expert Opin Pharmaco. 2012;13(7):1031–1043.
   PubMed Web of Science ®Google Scholar
• Ghavamzadeh A, Alimoghaddam K, Rostami S, et al. Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia. J Clin Oncol. 2011;29(20):2753–2757.
   PubMed Web of Science ®Google Scholar
• Platzbecker U, Avvisati G, Cicconi L, et al. Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non-high-risk acute promyelocytic leukemia: final results of the randomized Italian-German APL0406 trial. J Clin Oncol. 2017;35(6):605–612.
   PubMed Web of Science ®Google Scholar
• Rehman K, Naranmandura H. Arsenic metabolism and thioarsenicals. Metallomics. 2012;4:881–892.
   PubMed Web of Science ®Google Scholar
• Guo M, Wang W, Hai X, et al. HPLC-HG-AFS determination of arsenic species in acute promyelocytic leukemia (APL) plasma and blood cells. J Pharmaceut Biomed. 2017;145:356–363.
   PubMed Web of Science ®Google Scholar
• Gao C, Hu S, Guo M, et al. Clinical pharmacokinetics and safety profile of single agent arsenic trioxide by continuous slow-rate infusion in patients with newly diagnosed acute promyelocytic leukemia. Cancer Chemoth Pharm. 2018;82:229–236.
   PubMed Web of Science ®Google Scholar
• Guo M, Li J, Fan S, et al. Speciation analysis of arsenic in urine samples from APL patients treated with single agent As2O3 by HPLC-HG-AFS. J Pharmaceut Biomed. 2019;171:212–217.
   PubMed Web of Science ®Google Scholar
• Guo M, Wang B, Liu S, et al. Time course of arsenic species in red blood cells of acute promyelocytic leukemia (APL) patients treated with single agent arsenic trioxide. Expert Rev Clin Phar. 2019;12(4):371–378.
   PubMed Web of Science ®Google Scholar
• Chen GQ, Zhou L, Styblo M, et al. Methylated metabolites of arsenic trioxide are more potent than arsenic trioxide as apoptotic but not differentiation inducers in leukemia and lymphoma cells. Cancer Res. 2003;63(8):1853–1859.
   PubMed Web of Science ®Google Scholar
• Moe B, Peng H, Lu X, et al. Comparative cytotoxicity of fourteen trivalent and pentavalent arsenic species determined using real-time cell sensing. J Environ Sci-China. 2016;49:113–124.
   PubMedGoogle Scholar
• Kiguchi T, Yoshino Y, Yuan B, et al. Speciation of arsenic trioxide penetrates into cerebrospinal fluid in patients with acute promyelocytic leukemia. Leukemia Res. 2010;34(3):403–405.
   PubMed Web of Science ®Google Scholar
• Chen B, Cao F, Yuan C, et al. Arsenic speciation in saliva of acute promyelocytic leukemia patients undergoing arsenic trioxide treatment. Anal Bioanal Chem. 2013;405(6):1903–1911.
   PubMed Web of Science ®Google Scholar
• Iriyama N, Yoshino Y, Yuan B, et al. Speciation of arsenic trioxide metabolites in peripheral blood and bone marrow from an acute promyelocytic leukemia patient. J Hematol Oncol. 2012;5:1–7.
   PubMed Web of Science ®Google Scholar
• Yoshino Y, Yuan B, Miyashita SI, et al. Speciation of arsenic trioxide metabolites in blood cells and plasma of a patient with acute promyelocytic leukemia. Anal Bioanal Chem. 2009;393(2):689–697.
   PubMed Web of Science ®Google Scholar
• Hiemke C, Bergemann N, Clement H, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry. 2018;51(1–02):e1.
   PubMed Web of Science ®Google Scholar
• Mathews V, George B, Chendamarai E, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data. J Clin Oncol. 2010;28(24):3866–3871.
   PubMed Web of Science ®Google Scholar
• Fujisawa S, Ohno R, Shigeno K, et al. Pharmacokinetics of arsenic species in Japanese patients with relapsed or refractory acute promyelocytic leukemia treated with arsenic trioxide. Cancer Chemoth Pharma. 2007;59:485–493.
   PubMed Web of Science ®Google Scholar
• Fukai Y, Hirata M, Ueno M, et al. Clinical pharmacokinetic study of arsenic trioxide in an acute promyelocytic leukemia (APL) patient: speciation of arsenic metabolites in serum and urine. Biol Pharm Bull. 2006;29(5):1022–1027.
   PubMed Web of Science ®Google Scholar
• Christophe B, Gareth V, Angelo P, et al. Therapeutic drug monitoring in cancer – are we missing a trick? Eur J Cancer. 2014;50(12):2005–2009.
   PubMed Web of Science ®Google Scholar
• Eliasson E, Lindh JD, Malmström RE, et al., Therapeutic drug monitoring for tomorrow. Eur J Clin Pharmacol. 2013;69(1 Supplement):25–32.
   PubMedGoogle Scholar
• Engström KS, Broberg K, Concha G, et al., Genetic polymorphisms influencing arsenic metabolism: evidence from Argentina. Environ Health Perspect. 2007;115(4):599–605.
   PubMed Web of Science ®Google Scholar
• Lu J, Hu S, Wang W, et al. As3MT polymorphisms, arsenic metabolism, and the hematological and biochemical values in APL patients treated with arsenic trioxide. Toxicol Sci. 2018;166(1):219–227.
   PubMed Web of Science ®Google Scholar
• Liu WS, Wang XY, Lu J, et al. Polymorphisms in arsenic (+ 3 oxidation state) methyltransferase (AS3MT) predict the occurrence of hyperleukocytosis and arsenic metabolism in APL patients treated with As2O3. Arch Toxicol. 2020;94:1203–1213.
   PubMed Web of Science ®Google Scholar
• Asghari-Kia L, Bashash D, Safaroghli-Azar A, et al. Targeting human telomerase RNA component using antisense oligonucleotide induces rapid cell death and increases ATO-induced apoptosis in APL cells. Eur J Pharmacol. 2017;809:215–223.
   PubMed Web of Science ®Google Scholar
• Bashash D, Delshad M, Riyahi N, et al. Inhibition of PI3K signaling pathway enhances the chemosensitivity of APL cells to ATO: proposing novel therapeutic potential for BKM120. Eur J Pharmacol. 2018;841:10–18.
   PubMed Web of Science ®Google Scholar
• Sayyadi M, Safaroghli-Azar A, Pourbagheri-Sigaroodi A, et al. c-Myc inhibition using 10058-F4 increased the sensitivity of acute promyelocytic leukemia cells to arsenic trioxide via blunting PI3K/NF-κB axis. Arch Med Res. 2020;51(7):636–644.
   PubMed Web of Science ®Google Scholar